Get the Stockscreener App
3.62
3.21%
-0.12
Abcellera Biologics Inc stock is traded at $3.62, with a volume of 2.63M.
It is down -3.21% in the last 24 hours and down -8.82% over the past month.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
See More
Previous Close:
$3.74
Open:
$3.73
24h Volume:
2.63M
Relative Volume:
0.53
Market Cap:
$1.08B
Revenue:
$38.03M
Net Income/Loss:
$-146.40M
P/E Ratio:
-6.9615
EPS:
-0.52
Net Cash Flow:
$-121.38M
1W Performance:
+1.69%
1M Performance:
-8.82%
6M Performance:
+14.92%
1Y Performance:
+22.71%
1-Day Range:
$3.61
$3.86
1-Week Range:
$3.51
$3.86
52-Week Range:
$1.8906
$6.515
Abcellera Biologics Inc Stock (ABCL) Company Profile
Name
Abcellera Biologics Inc
Sector
Industry
Phone
(604) 559-9005
Address
150 W 4TH AVENUE, VANCOUVER
Compare ABCL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
3.62 | 1.12B | 38.03M | -146.40M | -121.38M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-07-25 | Resumed | Leerink Partners | Outperform |
| Aug-20-24 | Downgrade | The Benchmark Company | Buy → Hold |
| Feb-22-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Overweight |
| Nov-06-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Oct-13-23 | Resumed | Piper Sandler | Overweight |
| Feb-28-23 | Initiated | Cowen | Outperform |
| Dec-15-22 | Initiated | Goldman | Buy |
| Nov-16-22 | Initiated | Truist | Buy |
| Dec-21-21 | Initiated | The Benchmark Company | Buy |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Jan-05-21 | Initiated | BMO Capital Markets | Outperform |
| Jan-05-21 | Initiated | Berenberg | Buy |
| Jan-05-21 | Initiated | Credit Suisse | Outperform |
| Jan-05-21 | Initiated | SVB Leerink | Outperform |
| Jan-05-21 | Initiated | Stifel | Buy |
View All
Abcellera Biologics Inc Stock (ABCL) Latest News
AbCellera Appoints Dr. Stephen Quake to Board - MSN
Norges Bank Makes New $2.16 Million Investment in AbCellera Biologics Inc. $ABCL - MarketBeat
AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 - BioSpace
AbCellera Biologics’ Earnings Call: Key Insights - MSN
AbCellera Biologics Inc. (NASDAQ:ABCL) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Nasdaq Today Biotech Pioneer - Kalkine Media
AbCellera Biologics Inc (ABCL) Down 23% Since Q3 2025 Results - Finviz
Published on: 2025-12-04 02:33:18 - Newser
ABCL: Advancing a differentiated internal pipeline with strong capital support and end-to-end integration - TradingView
Can AbCellera Biologics Inc. (8QQ) stock resist broad market declines2025 Momentum Check & Safe Capital Preservation Plans - Newser
What dividend safety rating applies to AbCellera Biologics Inc. (8QQ) stock2025 Trade Ideas & Fast Gain Stock Tips - Newser
What makes AbCellera Biologics Inc. (8QQ) stock appealing to growth investorsPortfolio Growth Summary & Accurate Entry and Exit Point Alerts - Newser
9 Best Up and Coming Canadian Stocks to Buy - Insider Monkey
AbCellera Biologics Inc. (ABCL) Approved to Begin ABCL575 Trial for Atopic Dermatitis - MSN
Will AbCellera Biologics Inc. stock benefit from sector rotationJuly 2025 Short Interest & Breakout Confirmation Trade Signals - Newser
Published on: 2025-11-29 10:31:39 - earlytimes.in
AbCellera Biologics to change independent auditor after 2025 annual report By Investing.com - Investing.com Nigeria
AbCellera Biologics to change independent auditor after 2025 annual report - Investing.com
Insider Spends US$178k Buying More Shares In AbCellera Biologics - Yahoo Finance
Why AbCellera Biologics Inc. stock could rally in 2025July 2025 Final Week & Weekly Breakout Watchlists - BỘ NỘI VỤ
AbCellera biologics director Montalbano buys $178k in shares By Investing.com - Investing.com Nigeria
AbCellera biologics director Montalbano buys $178k in shares - Investing.com
AbCellera Biologics Inc. (ABCL) is a Buy at Stifel Nicolaus despite Wider Q3 Net Loss - Insider Monkey
13 Best Canadian Penny Stocks to Buy Right Now - Insider Monkey
AbCellera Biologics Inc. (ABCL) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
How AbCellera Biologics Inc. (8QQ) stock correlates with oil marketsJuly 2025 Price Swings & Expert Curated Trade Setups - newser.com
Is AbCellera Biologics Inc. (8QQ) stock safe for risk averse investors2025 Fundamental Recap & AI Driven Stock Reports - newser.com
How AbCellera Biologics Inc. (8QQ) stock compares with market leadersJuly 2025 Pullbacks & Verified Momentum Stock Watchlist - newser.com
Will AbCellera Biologics Inc. (8QQ) stock outperform energy sector in 2025Market Trend Summary & High Conviction Buy Zone Alerts - newser.com
How AbCellera Biologics Inc. (8QQ) stock reacts to weak economy2025 Trading Volume Trends & Safe Entry Zone Identification - newser.com
Is AbCellera Biologics Inc. (8QQ) stock at risk of policy regulationJobs Report & Daily Entry Point Alerts - newser.com
How AbCellera Biologics Inc. stock reacts to Fed rate cutsAnalyst Upgrade & Expert Curated Trade Setups - newser.com
Is a relief rally coming for AbCellera Biologics Inc. holdersDollar Strength & Fast Gain Stock Trading Tips - newser.com
What’s next for AbCellera Biologics Inc. stock priceQuarterly Investment Review & Capital Efficient Trade Techniques - newser.com
Abcellera Biologics Inc Stock (ABCL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):